Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists
dc.contributor.author | Reyes Martín, Efraim | |
dc.contributor.author | Prieto Aretxabaleta, Liher | |
dc.contributor.author | Milelli, Andrea | |
dc.date.accessioned | 2023-01-12T14:44:47Z | |
dc.date.available | 2023-01-12T14:44:47Z | |
dc.date.issued | 2022-12-29 | |
dc.identifier.citation | Molecules 28(1) : (2023) // Article ID 271 | es_ES |
dc.identifier.issn | 1420-3049 | |
dc.identifier.uri | http://hdl.handle.net/10810/59261 | |
dc.description.abstract | Majority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important to prepare these compounds in a safe, economic, and environmentally sustainable fashion. Asymmetric organocatalysis has a long history, but it began its renaissance era only during the first years of the millennium. Since then, this field has reached an extraordinary level, as confirmed by the awarding of the 2021 Chemistry Nobel Prize. In the present review, we wish to highlight the application of organocatalysis in the synthesis of enantio-enriched molecules that may be of interest to the pharmaceutical industry and the medicinal chemistry community. We aim to discuss the different activation modes observed for organocatalysts, examining, for each of them, the generally accepted mechanisms and the most important and developed reactions, that may be useful to medicinal chemists. For each of these types of organocatalytic activations, select examples from academic and industrial applications will be disclosed during the synthesis of drugs and natural products. | es_ES |
dc.description.sponsorship | The authors acknowledge the Spanish Agencia Estatal de Investigación (FEDER-PID2020-118422-GB-I00), the Basque Government (Grupos IT1558-22), and the University of Bologna for financial support. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2020-118422-GB-I00 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | asymmetric organocatalysis | es_ES |
dc.subject | chirality | es_ES |
dc.subject | chiral drugs | es_ES |
dc.subject | drug discovery | es_ES |
dc.subject | drug synthesis | es_ES |
dc.title | Asymmetric Organocatalysis: A Survival Guide to Medicinal Chemists | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2023-01-06T13:52:49Z | |
dc.rights.holder | © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/1420-3049/28/1/271 | es_ES |
dc.identifier.doi | 10.3390/molecules28010271 | |
dc.departamentoes | Química Orgánica e Inorgánica | |
dc.departamentoeu | Kimika Organikoa eta Ez-Organikoa |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).